Medicare's first-ever coverage of weight-loss drugs represents a landmark shift that could unlock demand from millions of previously underserved patients.
From manufacturers to distributors to pharmacies, the entire healthcare supply chain is positioned to benefit from the anticipated surge in prescription volume.
With proven market demand now backed by insurance coverage, biotech companies are racing to develop next-generation oral alternatives and improved delivery methods.
Market capitalisation breakdown and investor key points for the basket named 'Medicare's Weight Loss Drug Deal'.
LLY: $873.88B
NVO: $152.67B
VRTX: $103.89B
Recent Medicare agreements with major pharmaceutical companies like Eli Lilly and Novo Nordisk are making popular weight-loss drugs more affordable and accessible. This policy shift creates a significant investment opportunity as millions of new patients gain access to GLP-1 medications, potentially driving substantial revenue growth across the entire healthcare supply chain.
This group focuses on companies positioned to benefit from increased demand for weight-loss medications. It includes primary drug manufacturers, innovative biotechnology companies developing next-generation treatments, and essential supply chain partners like distributors and pharmacy retailers. The theme captures both immediate beneficiaries and long-term growth opportunities in this expanding market.
These stocks were handpicked by professional analysts based on their strategic positioning within the weight-loss drug ecosystem. From established pharmaceutical giants to innovative biotech companies developing oral alternatives, each represents a different way to benefit from the expected surge in demand following Medicare's landmark coverage expansion.
New agreements with Eli Lilly and Novo Nordisk are set to dramatically lower the cost of popular weight-loss drugs, making them accessible to millions through Medicare. This creates an investment opportunity centered on the major pharmaceutical companies involved and the broader supply chain that will support the expected surge in demand.
Erfahren Sie alles über diesen Aktienkorb. Lesen Sie unseren ausführlichen Artikel zu seinen Risiken und seinem Potenzial.
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Veröffentlicht am November 8
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
Eli Lilly & Co
LLY
Aktueller Kurs
$1,115.23
A primary manufacturer of popular GLP-1 drugs like Mounjaro and Zepbound, making it central to the theme of expanding access to weight-loss medication...
A primary manufacturer of popular GLP-1 drugs like Mounjaro and Zepbound, making it central to the theme of expanding access to weight-loss medications.
VERTEX PHARMACEUTICAL
VRTX
Aktueller Kurs
$515.44
A major biotechnology company with a robust pipeline, positioned to innovate and compete in the expanding market for metabolic and weight-loss therapi...
A major biotechnology company with a robust pipeline, positioned to innovate and compete in the expanding market for metabolic and weight-loss therapies.
Join Nemo FREE today and unlock every stock
Es dauert nur 60 Sekunden.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitiv Ltd.
Wenn Sie in diese Werte investieren:
In 12 Monaten könnte der Wert betragen:
+228.92%
Analysten erwarten im Durchschnitt, dass die Werte dieser Gruppe im nächsten Jahr um 228.92 % zulegen.
12 von 15 Werten dieser Gruppe werden von professionellen Analysten mit „Kaufen“ bewertet.
